Shares of CSL Limited (ASX:CSL) extended their impressive post-earnings rally on Wednesday, closing at A$166.48 after a 5.49% gain for the day. This follows a 17.25% surge the previous session, bringing the two-day advance to a remarkable 23.7%. The sharp upward move has added approximately A$14.5 billion to the company's market capitalization since Monday's close, underscoring the market's enthusiastic response to the biotech giant's annual results.
The stock's current price now stands 19.6% above the average analyst target of A$139.20, which was compiled from a survey of 16 analysts on August 7, before the results were released. This means that, based on pre-results consensus, the stock is now trading at a premium, suggesting potential downside if analysts do not revise their targets upward. The wide range of targets, from a low of A$108.00 to a high of A$198.05, highlights the uncertainty surrounding the stock's valuation following the results.
Market Reaction and Valuation
The rally has been driven by investors looking past the record statutory loss of US$2.6 billion, which was largely due to US$7.1 billion in pre-tax impairments. Instead, the market has focused on the underlying performance, with underlying NPATA declining just 2% to US$3.1 billion. The company also reported operating cash flow of US$3.5 billion, exceeding underlying NPATA, and a net debt to EBITDA ratio of 1.8 times, excluding restructuring and impairment costs.
Interim CEO Gordon Naylor described fiscal 2026 as "a year of reset," highlighting transformation savings of approximately US$176 million, which exceeded the initial target. This operational efficiency is expected to underpin underlying profit growth of around 5% in FY27. However, the outlook remains cautious, with revenue projected to stay largely flat at FY26 exchange rates.
Segment Performance and Outlook
CSL Behring, the company's core segment, saw revenue decline 1% to US$11.4 billion, with immunoglobulin sales flat at US$6.2 billion and albumin sales dropping 17% to US$1.1 billion due to Chinese cost controls. The new hereditary angioedema treatment, ANDEMBRY, contributed US$240 million in its first full year. CSL Vifor, on the other hand, grew revenue 3% to US$2.4 billion, but the company expects a significant 25% decline in FY27 sales for this division, pressured by generic iron alternatives and reimbursement changes. CSL Seqirus saw revenue fall 8% to US$2.0 billion, impacted by lower US vaccination uptake.
Capital Management and Dividends
CSL announced an additional A$1.1 billion share buyback, representing approximately 1.5% of Wednesday's market capitalization. The company maintained its final dividend at US$1.62, keeping the total payout steady at US$2.92 for the year. Shares will go ex-dividend on September 9, with the record date on September 10.
Analyst Views and Risks
Broker targets pre-dating the results are now all below the current share price, with the highest target from the survey at A$198.05 still representing a 19% potential upside. However, the consensus suggests limited room for further upside unless targets are revised. Key risks include the expected decline in Vifor, sluggish albumin prices in China, softer US vaccination trends, and the ongoing search for a permanent CEO, which could delay the company's reset.
Trading in Australia resumes at 10:00 AEST on Thursday. Over the next week, changes to analyst targets could take precedence over the ongoing accounting discussions. Investors will also watch whether the buyback can absorb profit-taking after such a sharp rebound.
